The following strains have been recommended by the World Health Organization (WHO) [1] for the 2014 
Timing
Vaccines should be given sufficiently early to provide protection for the winter. A protective antibody response takes about two weeks to develop.
Antiviral chemotherapy
At present, influenza A (H1N1) pdm09 and H3N2, and influenza B viruses remain sensitive to oseltamivir (and zanamivir). The dosages for treatment and post-contact prophylaxis (where indicated) are provided in Table 1 .
Antiviral chemoprophylaxis
Antiviral chemoprophylaxis for the contacts of persons infected with influenza is currently not recommended. Recent WHO recommendations advise presumptive treatment using the treatment regimen described above for higher-risk individuals (patients with severe immunosuppression or transplant patients) exposed to influenza instead of the previously recommended long-term lowerdose chemoprophylaxis regimen. These higher-risk individuals need to be carefully monitored during the influenza season for early signs and should then be treated immediately on suspicion of infection. For a more detailed description of antiviral management and chemoprophylaxis of influenza, please refer to the National Institute for Communicable Diseases Healthcare Workers Handbook on Influenza. [2] For the full report on recommended influenza vaccines, refer to the WHO recommendations. [1] 
